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Abstract
Background: A normally developed placenta is integral to a successful pregnancy. Preeclampsia (PE) and
intrauterine growth restriction (IUGR) are two common pregnancy related complications that maybe a result of
abnormal placental development. Placental microRNAs (miRNAs) have been investigated as potential biomarkers for
these complications, as they may play a role in placental development and pathophysiology by influencing gene
expression. The purpose of this study is to utilize next-generation sequencing to determine miRNA and gene
expression in human placental (chorionic villous) samples from three distinct patient groups with early-onset (EO)
PE, IUGR, or PE + IUGR.
Methods: Placental tissues were collected from four patient groups (control [N = 21], EO-PE [N = 20], EO-IUGR
[N = 18], and EO-PE + IUGR [N = 20]), and total RNA was used for miRNA and RNA sequencing on the Illumina
Hiseq2000 platform. For stringent differential expression analysis multiple analysis programs were used to
analyze both expression datasets in each patient group compared to gestational age-matched controls.
Results: Analysis revealed miRNAs and genes that are disease-specific, as well as others that were common
between disease groups, which suggests common underlying placental pathologies in EO-PE and EO-IUGR.
More specifically, 6 miRNAs and 22 genes were identified to be differentially expressed in all three patient
groups. In addition, integrative analysis between the miRNA and gene expression datasets revealed candidate
gene targets for miRNAs of interest.
Conclusions: Integration of miRNA and RNA profiling in the same three subgroups of pregnancy complications,
provides an alternate level of molecular information, in addition it can be used to better understand both unique and
common molecular mechanisms involved in the pathophysiology of these diseases.
Keywords: Intrauterine growth restriction, MicroRNA, Next-generation sequencing, Placenta, Preeclampsia
Background
Abnormal placental development in pregnancy may
result in complications such as preeclampsia (PE) and
intrauterine growth restriction (IUGR) [1, 2]. Preeclamp-
sia is a maternal pregnancy disorder characterized by
hypertension and proteinuria, and occurs in 2–8% of
pregnancies worldwide [3, 4]. Intrauterine growth re-
striction is poor fetal growth in utero with an expected
fetal weight lower than the 10th percentile estimated for
gestational age and gender, associated with abnormal
Dopplers in fetal and umbilical vessels [5, 6].
PE and IUGR are heterogeneous in etiology and can
be attributed to maternal, fetal and/or placental factors.
Maternal risk factors associated with PE include mater-
nal diabetes, pre-existing hypertension and obesity [4].
These maternal risk factors have also been found to be
associated with IUGR [5]. IUGR is also associated with
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fetal risk factors such as chromosomal abnormalities,
congenital anomalies and infection [5, 6]. A subset of
patients develop early-onset PE together with IUGR,
suggesting an overlap in the etiology underlying these
complications. Histopathology of placentae from PE and
IUGR pregnancies shows similar microscopic placental
abnormalities, supporting the concept of similar patho-
physiology underlying these two disorders [7].
Although the gestational age of the onset of signs and
symptoms is based on clinical outcomes and there is
some overlap, it is now recognized that the early- and
late- onset forms of the diseases may have different
pathophysiology [8]. Early-onset forms of these compli-
cations are more severe, where the mother and infant
are at higher risk of short- and long-term adverse health
outcomes [6, 9]. In PE pregnancies, mothers experience
a systemic disturbance mainly characterized by hyper-
tension and proteinuria, and are at higher risk of cardio-
vascular disease later in life [3, 4]. Meanwhile, the
newborns are usually born prematurely and are im-
pacted by the mortality and morbidity of preterm birth
in both PE and IUGR pregnancies.
Placental micro (mi)RNAs have been investigated for
their role in the growth and function of the placenta,
and for their potential use as diagnostic biomarkers due
to their ability to enter maternal circulation and are
detectable in the maternal plasma [10]. Epigenetics is
defined as the mechanisms regulating gene expression
without changes to the DNA sequence. Research has
identified a number of epigenetic mechanisms including
DNA methylation, histone modifications and non-
coding RNAs. MiRNAs are a class of non-coding RNAs
that can be tissue-specific and are encoded in the human
genome [11, 12]. The regulation of gene expression by
miRNAs by targeting mRNAs to transiently block
translation or degrade the mRNA without altering the
DNA sequence, classifies miRNAs as epigenetic regula-
tors [11, 12]. The final product of miRNA biogenesis is
an 18–22 base pair, single nucleotide strand, transcribed
in the nucleus and then transported into the cytoplasm
[11, 12]. Placenta-specific clusters have been identified
on chromosomes 14 and 19 [13, 14]. Differential expres-
sion analysis of miRNAs in the placenta has revealed a
dysregulation in miRNA expression in placentae from
pregnancies complicated with PE and IUGR [15, 16].
The most consistent finding is the increased expression
of miR-210 in PE placentae [15]. However, there are
differences in findings among previous studies that can
be attributed to: (i) the definition of patient groups; (ii)
differences in the platforms used to measure expression;
and (iii) analytical methods used to identify differentially
expressed miRNAs.
The purpose of this study is to utilize next-generation se-
quencing (NGS) to identify miRNAs and genes expressed
in the same placental tissues from three patient groups with
early-onset diseases. The patient groups include: PE only,
IUGR only, PE + IUGR, and gestational age-matched
controls without PE or IUGR. This analysis aims to identify
differentially expressed miRNAs and genes in each disease
group compared to the control group, and to integrate the
two expression datasets to identify potential gene targets
regulated by miRNAs.
Methods
Sample collection
Preeclampsia was defined as hypertension (blood pres-
sure > 140/90 mmHg) and proteinuria (≥ 300 mg in 24 h)
[3, 4]. Intrauterine growth restriction was defined as
estimated fetal weight below the 10th percentile for ges-
tational age and gender, associated with abnormal umbil-
ical and uterine artery Doppler evaluations [5, 6].
Patients with PE + IUGR presented with criteria afore-
mentioned for both diseases. Only patients diagnosed
prior to 34 weeks (early-onset) were included in this
study. Patients with preterm labor and no other compli-
cations before 34 weeks of gestation were recruited as
controls. Women with diabetes, gestational diabetes,
pre-existing hypertension, obvious chorioamnionitis,
alcohol/drug use, chromosomal or genetic abnormalities,
congenital anomalies, or infection were excluded. All
women enrolled in this study gave written informed con-
sent for the collection of samples and information. This
research was approved by the office of Human Research
Ethics at Western University (REB # 102621). Samples
were collected from two central and two peripheral por-
tions of the placenta within 30min of delivery. Central
samples were collected within a 5 cm radius from the
umbilical cord insertion site and the peripheral samples
were collected 2–3 cm from the edge of the placenta.
Full depth 1 cm × 1 cm tissue samples were excised, and
the maternal decidua was separated from the chorionic
villi using gross dissection. In this study, the maternal
and fetal components were separated and only the fetal
components (chorionic villi) were used for analysis. The
tissue samples were flash frozen in liquid nitrogen and
stored in − 80 °C until further analysis.
RNA isolation and sequencing
Total RNA was isolated from 80 to 100mg of tissue
samples from each of the four regions of each placenta
using the mirVana RNA isolation kit (Life Technologies,
Waltham, MA, USA). Sample quantity and quality was
checked using the Agilent Bioanalyzer 2100 (Agilent
Technologies, Palo Alto, CA, USA). Total RNA isolated
from central and peripheral samples of each placenta
was pooled in equal quantities for one representative
total RNA sample from each patient. Samples were then
sent to the Génome Québec Innovation Centre at
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McGill University (Montreal, QC, Canada) for library
preparation and sequencing. The Illumina Truseq RNA
and smRNA library preparation kits were used to pre-
pare mRNA and miRNA libraries respectively (Illumina,
San Diego, CA, USA). Samples were sequenced on the
Illumina HiSeq 2000.
Differential expression analysis
Using R v3.3.1 [17], three Bioconductor packages were
used for differential expression analysis, DESeq2 [18]
(Benjamini-Hochberg adjusted p-value < 0.01), edgeR
[19] (Benjamini-Hochberg adjusted p-value < 0.01) and
ALDEx2 [20] (effect > 0.8). Samples that contributed at
least the median plus twice the inter-quantile range
(IQR) of variance to the group were considered outliers
and were subsequently removed from the analysis [21].
Only miRNAs and genes identified by at least two pro-
grams were considered significant. To adjust for covari-
ates (fetal sex, maternal BMI, gestational age, and mode
of delivery (labor/no labor, C-section/vaginal)), surrogate
variable analysis (SVA R version 3.6) [22] was used with
DESeq2 and edgeR. The miRNA and gene expression
data are available from the Gene Expression Omnibus
(GEO) database under accession numbers GSE114349
and GSE114691, respectively.
Validation of miRNAs using qRT-PCR
Total RNA was reverse transcribed using TaqMan
advanced miRNA cDNA synthesis kit (Life Technolo-
gies, Waltham, MA, USA). Quantification of miRNAs
was completed using the TaqMan fast advanced PCR
master mix in conjunction with TaqMan miRNA expres-
sion assays (Life Technologies, Waltham, MA, USA).
For miRNA normalization, miR-191-5p was used as an
endogenous control [23, 24]. The ΔΔCt method was
used for analysis of real-time data to obtain a miRNA
fold-change relative to miR-191-5p expression. Mann-
Whitney-U was used for statistical analysis.
Target prediction and gene ontology
Spearman correlation co-efficient was used for correlation
analysis between miRNA and gene expression values. Only
correlation with a rs ≤ − 0.5 and p-value ≤0.01 was consid-
ered significantly negatively correlated. To further refine
results only genes with a fold-change ≤ − 1.5 or ≥ 1.5 were
included for target prediction analysis. Two target predic-
tion software were used: TargetScan (v7.1) [25] and
DIANA-microT-CDS (v5.0) [26]. Criteria used for final
selection of miRNA gene targets is in Additional file 1:
Table S1. Gene ontology analysis was completed using
WebGestalt (2013) [27].
Results
Patient selection criteria and principal component
analyses
Our aim was to select patients with primarily placental
factors underlying the diseases, therefore stringent inclu-
sion and exclusion criteria were used in patient recruit-
ment into the study. Patients with known maternal and/
or fetal risk factors were not included (see methods).
Clinical characteristics of the patient cohorts are de-
scribed in Table 1. There were no differences in mater-
nal age, BMI or gestational age at delivery between
patient groups. There were significant differences in
birth, placental weights and blood pressure between
patient groups with complicated pregnancies and gesta-
tional age-matched controls.
Preliminary exploratory analysis of the miRNA and gene
expression datasets had two aims: identification of outliers
and principal component analysis (PCA) to determine if
the samples separated by disease. Identified outliers were
removed prior to PCA. Based on miRNA expression data
sets, one patient each was removed from the PE only group
(N = 19) and from the control group (N = 20). Two patients
were removed from the IUGR group (N = 16), and none
were removed from the PE + IUGR group (N = 20). Based
on the gene expression data set, one patient was removed
from the PE only group (N = 19), three patients from the
IUGR only group (N = 15), and four patients from the PE +
IUGR group (N = 16). None were removed from the con-
trol group (N = 21).
Principal component analysis was then used to deter-
mine how patient samples cluster based on the expres-
sion data. Based on expression of all known human
miRNAs, samples clustered separately based on disease
status on the first principal component (Additional file 2:
Figure S1 a-c). Based on the transcriptome, samples also
clustered separately based on disease status on the first
principal component (Additional file 2: Figure S1 d-f ).
Patients with PE and IUGR clustered away from controls
with 15–40% of the variance in the data explained by the
first principal component.
Differential expression analysis of placental miRNAs
To identify differentially expressed miRNAs in each patient
group compared to gestational age- matched controls, three
different programs namely DESeq2, edgeR, and ALDEx2
were used. Only miRNAs identified by at least two were
considered significant. Using DESeq2 and edgeR, we
accounted for covariates in the model such as fetal sex, ma-
ternal BMI, gestational age, and mode of delivery. We iden-
tified 11 up-regulated miRNAs in the PE only samples
(Fig. 1a), 25 upregulated and 12 downregulated miRNAs in
IUGR samples (Fig. 1b), and 9 upregulated miRNAs in PE +
IUGR samples (Fig. 1c) (Additional file 3: Table S2). Com-
parison of all differentially expressed miRNAs, revealed 6
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miRNAs that are common to all three patient groups
(Fig. 2a). All of the differentially expressed miRNAs were
confirmed using qRT-PCR, with the exception of miR-
520a-3p in the IUGR group (Fig. 2b). Similarly, 3 miRNAs
that were common to patients with PE only (Fig. 2a) were
also validated using qRT-PCR (Fig. 2c).
Differential gene expression analysis in the patient
cohorts
The same differential expression analysis methods used for
the miRNA dataset were applied to the gene expression
dataset. In total, there were 275 differentially expressed
genes in the PE only samples, 155 differentially expressed
genes in the IUGR only samples, and 556 differentially
expressed genes in PE + IUGR samples (Additional file 4:
Table S3). Top ten up- and down- regulated genes in each
disease group are shown in Additional file 5: Figure S2 (a-
c). Comparison of differentially expressed genes in all
patient groups revealed 22 differentially expressed genes in
placental samples from all three disease groups (Fig. 3).
Other genes showed specificity to patients with PE or pa-
tients with IUGR, with 141 and 21 differentially expressed
respectively. Lists of common genes between patient
groups are found in Additional file 6: Table S4.
Target prediction and gene ontology analyses
As epigenetic regulators, abundantly expressed miRNAs
can impact gene expression by targeting mRNAs in the
Table 1 Clinical characteristics of the patient groups with complicated pregnancies and gestational age matched controls
1) p-value < 0.05 vs. control 2) p-value < 0.001 vs. control 3) p-value < 0.0001 vs. control 4) p-value < 0.01 vs. PE only 5) p-value < 0.0001 vs. IUGR only
Fig. 1 Heat maps depicting differentially expressed microRNAs in each patient group. Differential expression analysis revealed 11 upregulated
miRNA(s) in (a). Preeclamptic placenta 25 upregulated and 12 downregulated miRNAs in (b). Intrauterine growth restricted samples, and 9
upregulated miRNAs in (c). Preeclamptic and Intrauterine growth restricted samples. Three programs were used for differential expression
analysis, and only miRNAs identified by two or more programs were included in the final results
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cytoplasm. Inverse correlation analysis using Spearman’s
correlation co-efficient identified genes that negatively
correlated in expression to differentially expressed miR-
NAs. Identified genes had a significant negative correl-
ation with one or more miRNA. To further refine the
results, only candidate genes with fold-change (≤ − 1.5
or ≥ 1.5) were selected for further analysis. Target predic-
tion software programs (DIANA-microT-CDS and
TargetScan) were then used to identify predicted gene
targets for miRNAs. A summary of criteria used to select
appropriate gene targets is found in Additional file 1:
Table S1. This analysis resulted in 16 candidate gene tar-
gets (Fig. 4a) (Additional file 7: Table S5). The majority
of candidate gene targets identified were found in PE
only or PE + IUGR groups. Interestingly, there were can-
didate genes such as APLN, CSF1, FZD5, and TYRO3
that are potential targets of multiple miRNAs (Fig. 4a).
Gene ontology (GO) analysis of the 16 candidate gene
targets revealed that most genes are involved in import-
ant cellular functions including proliferation, migration,
communication and adhesion (Fig. 4b).
Discussion
Our study identified dysregulated miRNAs and genes in
placental samples that are common to three patient
groups with early-onset pregnancy complications. More
specifically, 6 miRNAs and 22 genes were found to be
commonly differentially expressed in patients with early-
onset PE, IUGR, and PE + IUGR, compared to gestational
age-matched controls. However, some miRNAs and genes
remained disease specific. To integrate the miRNA and
gene expression datasets, inverse correlation analysis re-
vealed candidate gene targets primarily involved in cell
functions such as proliferation and migration.
MicroRNAs identified to be common to all patient
groups, are some of the most commonly identified miR-
NAs in the literature. MicroRNAs identified in this study
have been identified in studies measuring miRNA ex-
pression in placental samples from primarily PE preg-
nancies. Studies assessing global miRNA expression in
placenta from IUGR pregnancies are scarce, potentially
due to heterogeneity of etiologies underlying this condi-
tion. Studies utilizing global miRNA expression analysis
Fig. 2 Comparing differentially expressed miRNAs between patient groups. a Six miRNAs are found to be common to all three patient groups,
whereas three miRNAs are specific to patients with preeclampsia. b Validation of miRNAs common to all three patient groups (with the exception
of miR-520a-3p in the IUGR only group), and c miRNAs common to preeclamptic patients using qRT-PCR. To find relative expression, delta-delta
CT was used and values were normalized to hsa-miR-191-5p expression. Data is shown as the mean ± S.E.M, significant differences were
determined by a Mann-Whitney U test. ****p-val < 0.0001 **p-val < 0.01
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Fig. 4 Target prediction and gene ontology analyses for all patient groups. a Identified candidate gene targets for miRNAs that have been
validated with qRT-PCR. Spearman correlation was used to identify genes that inversely correlate in expression to validated miRNAs, in each
patient group. Candidate gene targets were identified using prediction software DIANA-microT-CDS and TargetScan. b Gene ontology analysis for
identified candidate genes
Fig. 3 Comparing differentially expressed genes between patient groups. a Venn diagram shows the number of differentially expressed genes in
each patient group compared to the control group. Three programs were used for differential expression analysis (DESeq2, edgeR, ALDEx2), and
only genes identified by two or more programs were considered differentially expressed. b This analysis revealed 22 genes common to all three
patient groups
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in PE with overlapping findings to this present study are
found in Additional file 8: Table S6. One of the most
well characterized miRNAs in pregnancy complications
is miR-210 [15, 28]. Under hypoxic conditions, miR-210
is upregulated by the transcription factor HIF-1α [28].
The intrauterine environment in pregnancies compli-
cated by PE and/or IUGR has been suggested to be hyp-
oxic due to decreased perfusion of maternal blood to the
feto-placental unit. In our study, we identified that miR-
210-3p is common to all patient groups, whereas miR-
210-5p is common to patients with PE (Fig. 2). Gene
targets of miR-210 have also been investigated to identify
the impact of the upregulation of miR-210 on the pla-
centa during disease [28]. Identified targets for miR-210
include EFNA3 and HOXA9, which are important for
cell functions such as migration and invasion [28, 29]. In
our study, downregulated predicted targets of miR-210-
5p are also involved in cell migration, they include
APLN, CSF1, ITGAM, C3AR1, and SELE (Fig. 4,
Additional file 7: Table S5). These novel gene targets for
miR-210-5p have been identified to be downregulated in
patients with preeclampsia (± IUGR) in our study
(Additional file 4: Table S3). Gene targets such as APLN
and C3AR1 have been shown in the literature to be
down regulated in placental samples from PE patients
with an unknown underlying mechanism for dysregula-
tion [30, 31]. Apelin (APLN) is expressed in placental
syncytiotrophoblast cells, and evidence shows the in-
volvement of APLN in angiogenesis [30].
Other miRNAs such as miR-193b-3p/5p, and miR-
365a/b-3p have also been previously identified in studies
measuring miRNA expression in placental samples from
PE pregnancies [32–34] (Additional file 8: Table S6).
Identified gene targets for miR-193b-3p/5p are enriched
in gene ontology categories important for cell functions
such as cell proliferation, adhesion, and migration (Fig.
4a). Zhou et al. also showed increased expression of
miR-193b-3p and -5p in PE patients, and that miR-
193b-3p was found to decrease migration and invasion
of HTR-8/SVneo cells [34]. We also identified FZD5
(frizzled 5) as a candidate gene target for miR-365a/b-
3p, which belongs to the frizzled family of proteins,
known to be important during placental development
(Fig. 4). Frizzled 5 mRNA and protein have also been
reported to be down regulated in PE placenta [35]. In
the IUGR only group the majority of miRNAs remained
unique to that patient group (31/37). Of the 37 differen-
tially expressed miRNAs in the IUGR only group, 4
belonged to the C19MC (520a-3p, 520f-5p, 515-5p, 519-
5p) and 6 belonged to the C14MC (299-3p, 494-3p,
376a-5p, 382-3p, 154-3p, 369-3p), the two miRNA clus-
ters known to be specific to the placenta [1]. Enrichment
of gene targets in GO categories such as cell migration
and proliferation is not a surprising finding since recent
literature evidence has shown the role of miRNAs in
these functions, in addition to cell invasion and differen-
tiation [29, 34–36]. Findings are primarily reported in
placental or cancer studies, since there are many paral-
lels between placental and tumor development. In the
placenta these are important trophoblast cell functions,
impairment of these functions in trophoblast cells can
result in placental maldevelopment and insufficiency.
For example, intermediate cytotrophoblast cells must
migrate and differentiate into extravillous trophoblast
cells to then invade and remodel the maternal spiral
arteries to establish maternal blood flow. This is a com-
plex process and when impaired is thought to contribute
to the etiology of PE and IUGR.
Comparison between patient groups revealed a subset
of genes common to the three diseased patient groups.
A number of the differentially expressed genes the we
have identified in our diseased patient cohorts, have pre-
viously been identified to be dysregulated in placental
samples from complicated pregnancies. One example in-
cludes INHA (inhibin) and FSTL3 (follistatin-like 3),
both of which have been previously reported to be up-
regulated in PE placenta [37, 38]. In this study INHA
and FSTL3 are upregulated in pregnancies with IUGR as
well (Fig. 3, Additional file 4: Table S3). FSTL3 expres-
sion is enhanced by hypoxia and plays a role in tropho-
blast differentiation, migration and invasion [39, 40].
INHA also plays a role in trophoblast differentiation,
and syncytial fusion [41–43].
Differences observed between this current study and
other studies assessing global expression can be attrib-
uted to (i) strict patient selection criteria, (ii) platform
used to measure miRNA and gene expression, and (iii)
methods used for differential expression analysis. Pa-
tients in this study were strictly of early-onset disease,
and by excluding a number of maternal and fetal predis-
posing factors, the patients were better standardized as
to the pregnancy complications [8]. Despite this current
study being the largest to integrate miRNA and gene ex-
pression data in these patient cohorts to our knowledge,
a larger sample number or additional replication groups
would be beneficial. However, strict patient selection
criteria were beneficial, this is demonstrated in principal
component analyses based on miRNA and gene expres-
sion data in these patient groups that showed clear
segregation by disease status on the first principal
component. In addition, previous studies on PE do not
always stratify patients into PE only and PE + IUGR,
whereas in our study, these two patient populations were
segregated and treated as distinct populations. Recent
studies have shown distinct gene expression profiles for
different subclasses of PE (late vs. early, ± IUGR) [44, 45].
Leavey at al. combined microarray gene expression data
from previously published studies in PE placentae, and
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conducted unsupervised clustering analysis [45]. The
study identified three main subclasses of PE based on gene
expression - late-onset PE, which is mostly associated with
term deliveries and maternal risk factors (“maternal PE”);
early-onset PE, which is likely placental in origin and is
more frequently associated with IUGR (“canonical PE”);
and a third subclass of PE that is also severe and can co-
occur with IUGR but is likely due to poor maternal-fetal
compatibility (“immunologic PE”) [45]. Interestingly,
cluster analysis based on DNA methylation data in PE
placentae revealed a similar clustering pattern into the
three subclasses of PE [46]. In this study, 8763 and 340
differentially methylated sites were found in the “canon-
ical” and “immunologic” subclasses respectively [46].
Wilson et al. also showed differentially methylated sites, as
many as 599 sites, in EO-PE and only 5 in late-onset PE
[47]. These studies show differences in gene expression
and in epigenetic mechanisms between subclasses of PE,
emphasizing that each subclass has a unique underlying
pathophysiology. In addition, these studies demonstrate
the benefits of combining epigenetic and gene expression
data to improve our understanding of molecular mecha-
nisms in the placenta.
Next-generation sequencing (NGS) used in this study
to assess miRNA and gene expression has many advan-
tages compared to microarray platforms [48, 49]. The
detection capacity of microarrays is limited by the pre-
determined probes on the array platforms, whereas NGS
data can be used to align to the most updated sequence
information, which is beneficial for the discovery of new
miRNAs and genes. Moreover, NGS has a wider dy-
namic range and is therefore capable of detecting miR-
NAs and mRNAs that are expressed at low levels.
Interestingly, from our miRNA study, we identified that
our findings overlap more with studies that have also
used sequencing techniques compared to studies utiliz-
ing microarray technology [34, 50].
Lastly, the stringency of statistical analyses to identify
differentially expressed miRNAs and genes is beneficial
to increase confidence but could result in the exclusion
of some miRNAs and genes that may contribute to
pathogenesis of PE and/or IUGR. On the other hand,
methods for analyzing high-throughput data are cur-
rently not standardized, particularly normalization and
identification of differences [51]. Each program in this
study utilized a different approach to the normalization
and differential expression analysis. Therefore, using
stringent cut-off values and including only miRNAs and
genes identified by two or more programs increased the
reliability of our findings compared to using a single
approach for differential expression. Finally, the use of
preterm labor patients as controls is a limitation to this
study. Differential expression analysis in this study is
conducted in comparison to gestational age-matched
controls. Although it is beneficial to compare placental
samples of similar gestational age because of the prime
consideration of comparing placental tissues that are of
similar developmental stages, controls in this study are
from preterm births that may not be considered normal
nor healthy since evidence shows that preterm births are
a result of perturbations during gestation some of which
can be attributed to infection and inflammation in the
placenta. In the future, inclusion of both preterm and
term controls may be beneficial for understanding how
selection of control samples impacts results.
Conclusion
In summary, this study shows that maldevelopment
of the placenta early in gestation may manifest itself
into different complex diseases in the second and
third trimester, however some common underlying
pathophysiological mechanisms remain in the pla-
centa. Identification of common miRNAs and genes
that are dysregulated in all three patient groups sup-
ports this observation. The gene expression data set
allowed us to identify potential novel gene targets
that are primarily involved in cellular processes im-
portant for placental growth and function. Identified
candidate gene targets can be further experimentally
validated to demonstrate miRNA-mRNA interactions
and to assess the impact of miRNAs on gene expres-
sion. Since miRNAs can enter maternal circulation
during pregnancy, there are studies assessing the
diagnostic value of miRNAs in these pregnancy com-
plications. However, due to heterogeneity of samples
and differences between studies, no miRNAs with
good diagnostic value have been identified. In this
particular study, due to exclusion of many patients
with maternal and fetal risk factors, miRNAs identi-
fied in this study may be helpful in identifying an
obstetrical population at high risk of developing PE
or IUGR, that do not have obvious maternal and
fetal risk factors. Since the pathological processes
precede the clinical signs and symptoms of PE or
IUGR, it is possible that the miRNAs identified in
this study may be altered in the maternal circulation
early in pregnancy and may serve as potential bio-
markers that may predict PE or IUGR. Future stud-
ies may include analysis of maternal plasma samples
completed retrospectively by measuring miRNA
levels in plasma samples obtained early in pregnancy
as a part of routine clinical care to more accurately
assess diagnostic value across gestation. Continued
integration of epigenetic and gene expression data in
larger disease cohorts can validate findings and ex-
pand our understating of molecular mechanisms
impacting placental growth and function.
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